Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:granulomatosis_with_polyangiitis
|
| gptkbp:affects |
gptkb:skincare_product
lungs blood vessels nerves |
| gptkbp:associated_with |
gptkb:musician
allergic rhinitis hypereosinophilia atopy |
| gptkbp:caused_by |
autoimmune reaction
|
| gptkbp:clinical_trial |
ongoing
completed phase II phase III |
| gptkbp:complications |
lung damage
heart problems kidney damage nerve damage |
| gptkbp:end_of_life |
variable
increased with delay in treatment |
| gptkbp:events |
necessary
management of complications monitoring for relapses |
| gptkbp:first_described_by |
1951
|
| gptkbp:gender |
more common in males
|
| gptkbp:genetic_diversity |
HLA-DR B1 gene
IL-5 gene |
| https://www.w3.org/2000/01/rdf-schema#label |
Churg-Strauss syndrome
|
| gptkbp:is_known_for |
gptkb:eosinophilic_granulomatosis_with_polyangiitis
|
| gptkbp:is_popular_in |
rare
|
| gptkbp:premiered_on |
adulthood
|
| gptkbp:public_awareness |
patient advocacy groups
increased in recent years medical education initiatives |
| gptkbp:research_focus |
treatment efficacy
long-term outcomes pathogenesis |
| gptkbp:social_responsibility |
variable
blood tests imaging studies biopsy depends on severity depends on organ involvement |
| gptkbp:symptoms |
gptkb:asthma
fatigue fever sinusitis eosinophilia |
| gptkbp:treatment |
corticosteroids
immunosuppressants |